The Phase 2 clinical trial results of a COVID-19 vaccine developed by Taiwan-based Medigen Vaccine Biologics Corp. generated good data, experts have said, but they cautioned there was still no way to know how effectively it will protect people against getting the disease.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Politics
Lai's US$40 billion defense proposal 'a step towards peace': U.S. envoy
11/26/2025 02:18 PM - Business
Taiwan shares close up 1.85%
11/26/2025 01:50 PM - Society
Keelung train services disrupted after fugitive crashes car on railway
11/26/2025 12:52 PM - Politics
Citing 'peace through strength,' Lai pushes US$40 billion defense budget
11/26/2025 11:06 AM - Politics
Senators push bill to boost U.S. role in undersea cable security
11/26/2025 10:47 AM